Evaluating the da Vinci SP Surgical System for Gynecological Surgeries

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the clinical performance and safety of the da Vinci SP Surgical System, a robotic surgical tool, specifically for single-port gynecological surgeries. It will gather real-world evidence from both retrospective and prospective data involving female patients undergoing various gynecological procedures, such as hysterectomies and myomectomies. The goal is to provide insights into the effectiveness and safety of this technology in treating benign and malignant tumors within the Chinese population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Female patients who have received or plan to receive gynecological surgeries with the SP single-port robot such as radical hysterectomy, salpingectomy/oophorectomy, vaginal hysterectomy, total hysterectomy, myomectomy, ovarian cystectomy, deep endometriosis resection, pelvic and abdominal lymphadenectomy, sentinel lymph node resection by image development, uterus/vagino-sacral colpopexy, and high uterosacral ligament suspension.
2. Patients who voluntarily participate in the study and sign the ICF (or exempt from signature of the ICF as approved by the EC).

Exclusion Criteria:

1. Patients with missing data on the primary endpoint in retrospective cases;
2. Patients having any contraindications of single-port robot surgery;
3. The intraoperative anatomy demonstrate that minimally invasive surgery is not suitable;
4. Patients who are considered inappropriate to participate in this Study by investigators.

Where it's running

• Shanghai JiaoTong University School of Medicine affliated Ruijin Hospital
  Shanghai, Shanghai, China Recruiting

Study contacts

• Study coordinator: Weiwei Feng
• Email: wfeng7347@aliyun.com
• Phone: 13918551061

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AI-assisted 4D PET imaging to detect early pancreatic cancer lesions

  This study tests whether AI-assisted 4D long-axial PET imaging with FDG and FAPI can help detect early PDAC lesions in patients with suspected pancreatic tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07925125

• Urinary Cell-Free DNA Test for Urothelial Cancer Origin

  This study tests a urine-based cell-free DNA test to help diagnose urothelial cancer and identify whether it started in the bladder or upper urinary tract in adults.

  Recruiting Ruijin Hospital · Shanghai · NCT07888374

• Neoadjuvant therapy for locally advanced low rectal cancer: adding fruquintinib to short-course radiotherapy with tislelizumab and CAPOX

  This study tests whether adding fruquintinib to short-course radiotherapy plus tislelizumab and CAPOX before surgery helps people with locally advanced low rectal cancer achieve a better tumor response.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07888309

• Modular Robot-Assisted Esophagectomy vs. Conventional Minimally Invasive Esophagectomy for Esophageal Cancer

  This trial tests whether modular robotic-assisted esophagectomy using the Carina platform works better than conventional 3D thoracoscopic esophagectomy for people with resectable esophageal cancer.

  Recruiting Phase 3 Ruijin Hospital · Shanghai · NCT07888140

• Ivonescimab with pemetrexed and platinum chemotherapy as first-line treatment for advanced malignant pleural mesothelioma

  This study tests whether adding ivonescimab to standard pemetrexed plus platinum-based chemotherapy can help people with newly diagnosed advanced malignant pleural mesothelioma.

  Recruiting at 3 sites Phase 1/2 Ruijin Hospital · Shanghai, Shanghai Municipality and 2 other locations · NCT07885319

• Gecacitinib for patients with myeloid neoplasms and myelofibrosis undergoing allogeneic stem cell transplant

  This study tests whether taking gecacitinib around the time of allogeneic stem cell transplantation is safe and helps engraftment in adults with myeloid neoplasms and myelofibrosis.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai · NCT07883382

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.